ストックスクリーナーアプリを入手
0.3229
4.69%
-0.0159
プレマーケット:
.29
-0.0329
-10.19%
前日終値:
$0.3388
開ける：
$0.3697
24時間の取引高:
27.69M
Relative Volume:
1.58
時価総額：
$11.71M
収益：
-
当期純損益:
$-125.52M
株価収益率:
-0.0428
EPS:
-7.5468
ネットキャッシュフロー:
$-5.72M
1週間 パフォーマンス:
-9.55%
1か月 パフォーマンス:
+75.11%
6か月 パフォーマンス:
-73.96%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$0.2621
$0.3697
1週間の範囲:
$0.2621
$0.4368
52週間の値動き範囲:
$0.1513
$1.66
Lunai Bioworks Inc Stock (LNAI) Company Profile
名前
Lunai Bioworks Inc
セクター
電話
45 39179840
住所
CENTURY CITY MEDICAL PLAZA, SUITE 906 LOS ANGELES
Compare LNAI vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LNAI
Lunai Bioworks Inc
|
0.3229 | 12.29M | 0 | -125.52M | -5.72M | -7.5468 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Lunai Bioworks Inc (LNAI) 最新ニュース
Lunai Bioworks signs letter of intent with Geneial for rare disease data collaboration - Investing.com Australia
What's Behind The Jump In Lunai Bioworks Stock? - MSN
Lunai's rare disease data pact aims to build trial-ready patient groups - Stock Titan
Lunai Bioworks unit secures defense collaboration for AI chemical threat platform - MSN
Lunai Bioworks completes $20M transaction to acquire BBB - MSN
Reverse split range 1-for-3 to 1-for-30 proposed by Lunai Bioworks (NASDAQ: LNAI) - Stock Titan
Lunai Bioworks (LNAI) seeks approval for wide-range reverse stock split to support Nasdaq listing - Stock Titan
LNAI Stock Chart | LUNAI BIOWORKS INC (NASDAQ:LNAI) - ChartMill
Lunai Bioworks (NASDAQ: LNAI) Secures First Revenue-Generating Defense Collaboration Through BioSymetrics, Deploying AI Platform for Chemical Threat Assessment; Additional Engagements Under Discussion - Sahm
Lunai Bioworks (LNAI) Stock: New Defence Collaboration Unlocks Revenue and Innovation - parameter.io
Lunai Bioworks to acquire CNS drug delivery platform and Alzheimer’s assets for $20M - MSN
Lunai Bioworks (NASDAQ: LNAI) asks shareholders to approve up to 1‑for‑30 reverse split - Stock Titan
Lunai Bioworks Inc (2Q50.MU) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Lunai Bioworks Inc Com (LNAI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Lunai Bioworks Expands CNS Portfolio With $20M Acquisition - TipRanks
Lunai Bioworks Unveils $20M Preferred Investment and Debt-for-Equity Exchange to Advance CNS Assets - TradingView — Track All Markets
Lunai Bioworks (NASDAQ: LNAI) secures $20M CNS Alzheimer’s deal and converts secured debt - Stock Titan
Lunai Bioworks acquires CNS drug delivery tech for $20M By Investing.com - Investing.com Australia
Why did LNAI stock skyrocket over 130% pre-market today? - MSN
Microcap March Madness: LNAI, FAGI, VSA, LNKS Sweet 16 Underdog Watch - Barchart.com
Lunai Bioworks Acquires $20M in BBB Delivery Tech, CNS Alzheimer’s Assets from Clemann Group - Contract Pharma
Why did LNAI stock skyrocket over 130% pre-market today? | Tap to know more | Inshorts - Inshorts
Lunai Bioworks, Inc. (LNAI) Stock: No-Reset Convertible Deal Boosts CNS Drug Development Edge - parameter.io
Lunai Bioworks (LNAI) Acquires BBB Technology in $20M Deal - GuruFocus
Why Did LNAI Stock Surge Over 25% Today? - Stocktwits
Lunai Bioworks Executes $20M Strategic Transaction at Fixed $1.50 Conversion, Acquiring BBB Delivery Platform for CNS Alzheimer's Therapies with Broad CNS Delivery Applications - Finviz
LNAI Enhances CNS Pipeline with Strategic Acquisition - GuruFocus
Why Did LNAI Stock Skyrocket Over 130% Pre-Market Today? - stocktwits.com
Lunai Bioworks acquires CNS drug delivery tech for $20M - Investing.com
Lunai Bioworks Executes $20M Strategic Transaction At Fixed $1.50 Conversion, Acquiring Bbb Delivery Platform For Cns Alzheimer's Therapies With Broad Cns Delivery Applications - TradingView
Lunai Bioworks Inc. has executed binding agreement to acquire BBB delivery technology and CNS Alzheimer's drug assets of Clemann Group from Clemann Group for $20 million. - marketscreener.com
If You Invested $1,000 in Renovaro (RENB) - Stock Titan
$400M to $1.2 Billion US Countermeasures Program Presents Huge Opportunity for New AI Platform to Meet Emerging Battlefield and Terrorism Threats: Lunai Bioworks (Nasdaq: LNAI) - Barchart.com
$400M to $1.2 Billion US Countermeasures Program Presents Huge - openPR.com
Targeting the Billion-Dollar U.S. Countermeasure Market With AI-Driven Biodefense Platform: Lunai Bioworks (N A S D A Q: LNAI) - PRLog
Lunai Bioworks Engages Initial U.S. Countermeasure Opportunities Following $400M–$1.2B Consortium Launch - weeklyvoice.com
Lunai Bioworks (NASDAQ: LNAI) Launches National Chemical Defense Consortium Targeting $400M-$1.2B U.S. Countermeasure Programs; 3-Year AI Antidote Development Model - Finviz
LNAI Initiates Consortium to Speed Up Chemical Countermeasure De - GuruFocus
Lunai Bioworks (LNAI) Stock Forecast and Price Target 2026 $LNAI - MarketBeat
LNAI stock: Lunai Bioworks (NASDAQ) $0.52, vol 509,735,274 on 17 Mar 2026: monitor AI oncology signals - Meyka
Lunai Bioworks Inc (LNAI) 財務データ
収益
当期純利益
現金流量
EPS
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):